Published • loading... • Updated
GLP-1 agonists may help people with diabetes and long COVID, study in mice suggests
In mice, the drugs normalized fibrosis-related genes and reduced lung scarring, but researchers said the findings are preliminary and based on a small sample.
Summary by Medical Xpress
2 Articles
2 Articles
GLP-1 agonists may help people with diabetes and long COVID, study in mice suggests
GLP-1 agonists have become popular treatments for weight loss and type 2 diabetes, and newer studies suggest other health benefits as well. Findings from experiments on mice, published in the Journal of Virology, suggest that the drugs may offer benefits to another patient population: people with type 2 diabetes who suffer from pulmonary fibrosis months or years after infection with SARS-CoV-2, the virus that causes COVID-19.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center2Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
